nasdaqexel
In the wake of a new EXEL stock buyback, the cancer therapies maker is in the sights of investors looking to make board changes It has been an eventful start to the week for investors of genomics-based drug discovery outfit Exelixis (NASDAQ:EXEL), after the company announced a share buyback worth $550 million pre-market and received an activist filing post-market. Q4 2022 hedge fund letters, conferences and more Find A Qualified Financial AdvisorEach advisor has been vetted by SmartAsset and is held to a fiduciary standard to act in your best interests. If you're ready to be matched with local...
ValueWalk
Pfizer Inc. could outperform with consistent dividend and revenue growth.Regeneron Pharmaceuticals Inc. has a high P/E with a low upside but value could increase on continued revenue growth.Innoviva Inc. started the year heavily down but strong revenue gains could offset projected losses.Exelixis Inc. is near its 52-week bottom but a furtive P/E and impressive upside could push it to a 52-week high.5 stocks we like better than ExelixisQ4 2022 hedge fund letters, conferences and more Find A Qualified Financial AdvisorEach advisor has been vetted by SmartAsset and is held to a fiduciary standard...
ValueWalk
閲覧を続けるには、ノアドット株式会社が「プライバシーポリシー」に定める「アクセスデータ」を取得することを含む「nor.利用規約」に同意する必要があります。
「これは何?」という方はこちら